德克利斯塔马布:作用机制,临床和翻译科学
Yue Guo1, Natalia A Quijano Cardé1, Lijuan Kang1
1Janssen Research & Development, Spring House, Pennsylvania, USA.
Clinical and translational science
|January 24, 2024
概括
德克利斯塔马布是一种用于多发性骨髓瘤 (MM) 的新型双特异性抗体. 它针对骨髓瘤细胞的BCMA和T细胞的CD3,在复发性/耐药性MM患者中显示出高响应率.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
背景情况:
- 多发性髓瘤 (MM) 是一种无法治愈的血液性恶性瘤.
- B细胞成熟抗原 (BCMA) 是MM中一个有前途的治疗点.
- 对于复发性/耐药性MM,需要新的治疗策略.
研究的目的:
- 评估teclistamab的疗效和安全性,一个针对BCMA的双特异性抗体,在复发/耐药多发性髓瘤患者中.
- 根据安全性,疗效和药理动力学/药理动力学数据,确定特克利斯塔马布的最佳剂量方案.
主要方法:
- 德克利斯塔马布向T细胞上的CD3和髓瘤细胞上的BCMA,诱导T细胞介导的瘤细胞溶解.
- 在逐步增加剂量后,建立了一个每周皮下1.5mg/kg的剂量方案.
- 暴露-反应分析为剂量选择提供了信息.
主要成果:
- 在三次暴露的复发性/耐药性MM患者中,teclistamab的整体响应率为63%,完整响应率为45.5%或更好.
- 响应的平均持续时间为22个月.
- 常见的不良事件包括细胞因子释放综合征,血液异常和感染.
结论:
- 德克利斯塔马布为复发性/耐药性多发性髓瘤患者提供了一个新的治疗选择.
- 既定的剂量方案支持深度和持久的反应.
- 目前正在对单疗法和组合疗法中的特克利斯塔马布进行进一步的研究.
更多相关视频
相关概念视频
Tumor Immunotherapy
526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
T Cell Activation and Clonal Selection
735
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
735
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)

